retatrutide parkinson's disease clinical trial Reta data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP To learn more, visit: https://www.clinicaltrials.gov/study/NCT05819866

This review study analyzes human and animal trials of various GLP-1 medications for their role in addressing the hallmarks of aging, such as mitochondrial function and oxidative stress, including low-dose protocols via injection for Parkinson's patients on exenatide

Limited thoracic rotation forces compensatory movement patterns that reduce power output and increase injury risk

It revitalizes me, and I feel amazing, she says

Even otherwise dispassionate media outlets have labelled these drugs miracle drugs that will change the world

GLP-1 receptor agonists such as semaglutide (marketed under brand names Ozempic, Wegovy, and Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (marketed under brand names Mounjaro and Zepbound) are FDA-approved prescription medications for specific uses in type 2 diabetes management and, in some cases, chronic weight management